Compare DexCom, Inc. (DXCM) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Novavax Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: DexCom, Inc. is far larger — about 17.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Novavax Inc for 59 Days on average.
| DXCM | NVAX | |
|---|---|---|
Market Cap | $31.86B | $1.82B |
Volume | 3,607,070 | 6,198,505 |
Sector | Health | Health |
52-Week High | $92.34 | $12.56 |
52-Week Low | $54.84 | $6.22 |
Typical Hold Time | 62 Days | 59 Days |
Enterprise Value | $31.32B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
